Nufarm (ASX:NUF)- CEO, Greg Hunt
CEO, Greg Hunt
Source: Nufarm
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • The US Food and Drug Administration (FDA) recognises Nufarm’s (NUF) Nuseed omega-3 canola oil as a new dietary ingredient
  • The company has created a plant-based source of omega-3 fatty acids as an alternative to fish oil, the most common source of omega-3
  • According to NUF, the oil will help reduce pressure on wild-fish stocks
  • CEO Greg Hunt said FDA approval is a huge milestone for the company
  • On market close for the day, Nufarm was up 3.21 per cent and is trading at $4.50 per share

The US Food and Drug Administration (FDA) has recognised Nufarm’s (NUF) Nuseed omega-3 canola oil as a new dietary ingredient.

The company has created a plant-based source of omega-3 fatty acids and is an alternative to fish oil, the most common source of omega-3.

Omega-3 have several health benefits, such as lowering blood pressure and raising.

Nuseed’s omega-3 canola helps fill the gap between how much long-chain omega-3 is needed to support human and animal nutrition and how little the ocean can sustainably provide.

CEO Greg Hunt said FDA approval is a huge milestone for the company.

“The FDA’s acknowledgment along with our recently completed human clinical trial, allows us to progress our plans to expand into the human nutrition market and meet a growing demand for plant-based omega-3 essential oil options,” Mr Hunt said.

“With FDA recognition of Nuseed’s conclusion that Nutriterra is a safe new dietary ingredient, we are well placed to secure commercial partnerships that will attract new consumers, enter into new segments and raise consumption of omega-3.”

Notably, a human trial was conducted with the omega-3 canola oil and showed participants absorbing the oil’s omega-3s.

On market close for the day, Nufarm was up 3.21 per cent and is trading at $4.50 per share.

NUF by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…